PRESSRELEASES
12 May, 2026
Bulletin from the Annual General Meeting of Nanexa AB
The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on May 12, 2026, at which meeting submitted proposals were passed. The complete proposals for resolutions are set out in the AGM notice.
READ MORE29 April, 2026
Nanexa publishes interim report for January-March 2026
Opened the year with strong preclinical results for once-monthly and quarterly dosing of semaglutide
READ MORELATEST REPORTS
PRESENTATIONS
29 April 2026
Q1 report commentary with CEO David Westberg
19 February 2026
Q4 report commentary with CEO David Westberg and Chairman of the Board Göran Ando
11 December 2025
Nanexa and Moderna enter into license and option agreements
6 November 2025
Q3 report commentary with CEO David Westberg
MEET NANEXA
18–20 May 2026
Nanexa will participate in DDF Summit 2026 in Berlin, Germany on 18-20 May
Dr. Joel Hellrup, Head of Pharmaceutical R&D at Nanexa, will give a presentation at 08:35am on Tuesday, May 19 at Maritim proArte Hotel Berlin on PharmaShell®: Atomic layer deposition enabling once‑monthly and once‑quarterly semaglutide depots, with clinical proof‑of‑concept from liraglutide.
22–25 June 2026